28.86
price down icon3.93%   -1.18
after-market アフターアワーズ: 28.86
loading
前日終値:
$30.04
開ける:
$29.75
24時間の取引高:
687.84K
Relative Volume:
1.00
時価総額:
$1.80B
収益:
$32.08M
当期純損益:
$-169.77M
株価収益率:
-10.16
EPS:
-2.8418
ネットキャッシュフロー:
$-147.70M
1週間 パフォーマンス:
-1.50%
1か月 パフォーマンス:
-11.80%
6か月 パフォーマンス:
-4.88%
1年 パフォーマンス:
+124.59%
1日の値動き範囲:
Value
$28.70
$30.00
1週間の範囲:
Value
$28.49
$30.92
52週間の値動き範囲:
Value
$12.40
$40.22

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name
名前
Stoke Therapeutics Inc
Name
セクター
Healthcare (1079)
Name
電話
781-430-8200
Name
住所
45 WIGGINS AVENUE, BEDFORD, MA
Name
職員
170
Name
Twitter
@stoketx
Name
次回の収益日
2026-08-11
Name
最新のSEC提出書
Name
STOK's Discussions on Twitter

Compare STOK vs VRTX, REGN, ARGX, RVMD, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
STOK icon
STOK
Stoke Therapeutics Inc
28.86 1.83B 32.08M -169.77M -147.70M -2.8418
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
477.10 121.57B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
762.63 69.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
853.82 55.61B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
187.53 39.98B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
316.01 33.81B 5.76B 514.49M 1.10B 4.4813

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-02-05 開始されました Guggenheim Buy
2026-01-05 再開されました Chardan Capital Markets Buy
2025-07-18 開始されました Jefferies Buy
2024-12-20 開始されました Chardan Capital Markets Buy
2024-10-14 再開されました Leerink Partners Outperform
2024-03-26 アップグレード TD Cowen Market Perform → Outperform
2023-11-20 再開されました JP Morgan Neutral
2023-07-25 ダウングレード TD Cowen Outperform → Market Perform
2023-05-01 アップグレード BofA Securities Underperform → Neutral
2023-04-26 再開されました Canaccord Genuity Buy
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2022-10-24 アップグレード SVB Leerink Mkt Perform → Outperform
2022-01-31 開始されました Jefferies Buy
2021-12-03 開始されました BofA Securities Buy
2021-11-22 アップグレード JP Morgan Neutral → Overweight
2021-05-18 開始されました UBS Neutral
2021-05-10 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-02-10 ダウングレード Wedbush Outperform → Neutral
2020-12-15 再開されました H.C. Wainwright Buy
2020-12-11 繰り返されました Needham Buy
2020-10-23 開始されました Cantor Fitzgerald Overweight
2020-09-29 再開されました JP Morgan Neutral
2020-09-29 開始されました Needham Buy
2019-12-18 開始されました Wedbush Outperform
2019-11-12 開始されました BTIG Research Buy
2019-10-25 開始されました H.C. Wainwright Buy
2019-07-15 開始されました Canaccord Genuity Buy
2019-07-15 開始されました Cowen Outperform
2019-07-15 開始されました Credit Suisse Outperform
2019-07-15 開始されました JP Morgan Overweight
すべてを表示

Stoke Therapeutics Inc (STOK) 最新ニュース

pulisher
Jul 28, 2026

EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat

Jul 28, 2026
pulisher
Jul 28, 2026

Stoke Therapeutics Inc (STOK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 28, 2026
pulisher
Jul 27, 2026

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates - BioSpace

Jul 27, 2026
pulisher
Jul 27, 2026

Stoke Therapeutics Inc (STOK) Cash Flow - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Stoke Therapeutics Inc (STOK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Stoke Therapeutics Inc (STOK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Stoke Therapeutics Inc (STOK) Institutional Confidence - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Troluce Capital Advisors LLC Buys Shares of 652,800 Stoke Therapeutics, Inc. $STOK - MarketBeat

Jul 27, 2026
pulisher
Jul 27, 2026

Stoke Therapeutics Inc (STOK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Stoke Therapeutics Inc (STOK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

STOK|Stoke Therapeutics Inc|Price:29.320|Chg%:+0.020 - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

TradingKey - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Granahan Investment Management LLC Has $10.93 Million Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat

Jul 25, 2026
pulisher
Jul 25, 2026

Stoke Therapeutics, Inc. Revenue Breakdown – NASDAQ:STOK - TradingView

Jul 25, 2026
pulisher
Jul 24, 2026

Siren L.L.C. Sells 252,000 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat

Jul 24, 2026
pulisher
Jul 24, 2026

Stoke Therapeutics Inc (STOK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 24, 2026
pulisher
Jul 23, 2026

(STOK) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Jul 23, 2026
pulisher
Jul 22, 2026

Stoke Therapeutics (STOK) Edges Higher, Testing Resistance at $30.41ADD Alert - dars.gov.et

Jul 22, 2026
pulisher
Jul 19, 2026

Stoke Therapeutics Inc (STOK) - MSN

Jul 19, 2026
pulisher
Jul 19, 2026

Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch (NASDAQ:STOK) - Seeking Alpha

Jul 19, 2026
pulisher
Jul 17, 2026

Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement - Bitget

Jul 17, 2026
pulisher
Jul 17, 2026

Form 4 Stoke Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria

Jul 17, 2026
pulisher
Jul 17, 2026

Form 4 Stoke Therapeutics Inc For: 17 July - Investing.com India

Jul 17, 2026
pulisher
Jul 17, 2026

Stoke Therapeutics (STOK) director gifts 303,190 options to trust - Stock Titan

Jul 17, 2026
pulisher
Jul 17, 2026

Stoke Therapeutics (STOK) awards 225,000 stock options to Chief Scientific Officer - Stock Titan

Jul 17, 2026
pulisher
Jul 17, 2026

Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report - Stock Titan

Jul 17, 2026
pulisher
Jul 17, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 16, 2026 - BioSpace

Jul 17, 2026
pulisher
Jul 16, 2026

Stoke Therapeutics grants CSO McCauley options for 225,000 shares at $29.91 each - Bitget

Jul 16, 2026
pulisher
Jul 14, 2026

Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group - MarketBeat

Jul 14, 2026
pulisher
Jul 14, 2026

Stoke Therapeutics (STOK) Declines Slightly as Stock Consolidates Near ResistanceStock Analysis - dars.gov.et

Jul 14, 2026
pulisher
Jul 13, 2026

Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44 - Moomoo

Jul 13, 2026
pulisher
Jul 13, 2026

Stoke Therapeutics appoints Thomas McCauley as CSO By Investing.com - Investing.com India

Jul 13, 2026
pulisher
Jul 13, 2026

Stoke Tx appoints Thomas McCauley as CSO - The Pharma Letter

Jul 13, 2026
pulisher
Jul 13, 2026

Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer - citybiz

Jul 13, 2026
pulisher
Jul 13, 2026

Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential - Investing.com UK

Jul 13, 2026
pulisher
Jul 13, 2026

Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer - Contract Pharma

Jul 13, 2026
pulisher
Jul 13, 2026

Stoke Therapeutics Announces Appointment of Thomas McCauley as Chief Scientific Officer - marketscreener.com

Jul 13, 2026
pulisher
Jul 13, 2026

Stoke Therapeutics appoints Thomas McCauley as CSO - Investing.com

Jul 13, 2026
pulisher
Jul 13, 2026

Goldman Sachs Initiates Coverage on Stoke Therapeutics With Buy Rating, $44 Price Target - marketscreener.com

Jul 13, 2026
pulisher
Jul 13, 2026

Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer - Business Wire

Jul 13, 2026
pulisher
Jul 13, 2026

STOK Initiates Coverage On Goldman Sachs -- Price Target Announced at $44 - GuruFocus

Jul 13, 2026
pulisher
Jul 13, 2026

Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential By Investing.com - Investing.com South Africa

Jul 13, 2026
pulisher
Jul 12, 2026

Candriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat

Jul 12, 2026
pulisher
Jul 12, 2026

Stoke Therapeutics Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - Moomoo

Jul 12, 2026
pulisher
Jul 10, 2026

Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT) - TradingView

Jul 10, 2026
pulisher
Jul 10, 2026

Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK) - The Globe and Mail

Jul 10, 2026
pulisher
Jul 10, 2026

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Jul 10, 2026
pulisher
Jul 09, 2026

Stoke Therapeutics Announces Updates to Timelines for the Complet - The National Law Review

Jul 09, 2026
pulisher
Jul 09, 2026

Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Jul 09, 2026
pulisher
Jul 08, 2026

Stoke Therapeutics highlights antisense pipeline as genetic medicine interest grows - AD HOC NEWS

Jul 08, 2026

Stoke Therapeutics Inc (STOK) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$90.58
price down icon 2.44%
$119.52
price down icon 2.82%
$33.91
price down icon 1.77%
$58.43
price down icon 1.00%
$205.52
price up icon 0.02%
ONC ONC
$316.01
price down icon 1.88%
大文字化:     |  ボリューム (24 時間):